|
|
||||||||
-Secreting, CD8+ CTL In Vivo1
Center for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada
By using adoptive transfer of Ag-loaded bone marrow-derived
dendritic cells (BMDC), we have established an in vivo model of CTL
priming. Activation of CTL in these experiments required both
CD4+ T cells and CD154, demonstrating that this model
reflects CD4+ T cell-dependent dendritic cell (DC)
licensing. Because IL-12 has been suggested to play an important role
in CTL activation by DC, we examined the ability of BMDC to prime CTL
in the complete absence of IL-12 using p40-deficient mice. We observed
that the absence of IL-12 does not affect the phenotype or
allostimulatory function of BMDC after in vitro maturation. Moreover,
there was no difference in the ability of Ag-loaded DC to elicit CTL
cytotoxicity, whether the Ag was delivered by virus infection or
peptide pulsing. Equal frequencies of Ag-specific, IFN-
-secreting
CD8+ T cells developed in both wild-type and
IL-12-deficient backgrounds. Finally, CTL generated in the
IL-12-deficient environment were capable of protecting immunized mice
against tumor challenge, demonstrating that these CTL were fully
functional, despite the absence of IL-12 during the maturation process
in vivo. These results indicate that IL-12 is not critical for the
development of IFN-
secreting, CD8+ T cells and that
another mechanism must be used by licensed DC to prime and activate
CTL.
This article has been cited by other articles:
![]() |
M. Li, X. Zhang, X. Zheng, D. Lian, Z.-X. Zhang, H. Sun, M. Suzuki, C. Vladau, X. Huang, X. Xia, et al. Tolerogenic dendritic cells transferring hyporesponsiveness and synergizing T regulatory cells in transplant tolerance Int. Immunol., February 1, 2008; 20(2): 285 - 293. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Eguchi, N. Kuwashima, M. Hatano, F. Nishimura, J. E. Dusak, W. J. Storkus, and H. Okada IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity J. Immunol., June 1, 2005; 174(11): 7194 - 7201. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, and M. P. Colombo Redirecting In vivo Elicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection Cancer Res., April 15, 2005; 65(8): 3437 - 3446. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. P. Singh, S. Singh, P. Ravichandran, D. D. Taub, and J. W. Lillard Jr. Viral Macrophage-Inflammatory Protein-II: A Viral Chemokine That Differentially Affects Adaptive Mucosal Immunity Compared with Its Mammalian Counterparts J. Immunol., November 1, 2004; 173(9): 5509 - 5516. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lane, J. Leitch, X. Tan, J. Hadjati, J. L. Bramson, and Y. Wan Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin Cancer Res., February 15, 2004; 64(4): 1509 - 1514. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. van den Broeke, E. Daschbach, E. K. Thomas, G. Andringa, and J. A. Berzofsky Dendritic Cell-Induced Activation of Adaptive and Innate Antitumor Immunity J. Immunol., December 1, 2003; 171(11): 5842 - 5852. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dayball, J. Millar, M. Miller, Y. H. Wan, and J. Bramson Electroporation Enables Plasmid Vaccines to Elicit CD8+ T Cell Responses in the Absence of CD4+ T Cells J. Immunol., October 1, 2003; 171(7): 3379 - 3384. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tschoep, T. C. Manning, H. Harlin, C. George, M. Johnson, and T. F. Gajewski Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines J. Leukoc. Biol., July 1, 2003; 74(1): 69 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Lillard Jr, U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity Blood, February 1, 2003; 101(3): 807 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gri, E. Gallo, E. Di Carlo, P. Musiani, and M. P. Colombo OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response J. Immunol., January 1, 2003; 170(1): 99 - 106. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |